Reata Pharmaceuticals Announces First Quarter 2018 Financial Results and an Update on Development Programs

Reata Pharmaceuticals (Nasdaq:RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company’s product development programs and announced financial...

Anthera Finished Dosing In Clinical Study

Anthera Pharmaceuticals completed the dosing of a recent randomized, double-blind, placebo-controlled clinical study of blisibimod on patients with Berger's disease.